Navigation Links
Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
Date:8/13/2009

r and Trust Company, 59 Maiden Lane, Plaza Level, New York, NY 10038. The Information Agent for the tender offer is Georgeson Inc., 199 Water Street, 26th Floor, New York, NY 10038.

About Hisamitsu

Hisamitsu Pharmaceutical Co., Inc. is a leading pharmaceutical company that develops and markets prescription and over-the-counter ("OTC") pharmaceutical products using transdermal delivery systems technology. Its leading product in prescription pharmaceuticals is its Mohrus((R)) series (ketoprofen patch for pain), and its leading brand in the OTC business is Salonpas((R)). The company was founded in 1847 and is located in Saga, Japan. Additional information is available through its corporate website, http://www.hisamitsu.co.jp.

Additional Information

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Noven. Hisamitsu has filed a tender offer statement with the SEC, and mailed an offer to purchase, forms of letter of transmittal and related documents to Noven shareholders. Noven has filed with the SEC, and mailed to Noven shareholders, a solicitation/recommendation statement on Schedule 14D-9. These documents contain important information about the tender offer and shareholders of Noven are urged to read them carefully.

These documents are available at no charge at the SEC's website at www.sec.gov. The tender offer statement and the related materials may be obtained for free by directing a request by mail to Georgeson Inc., 199 Water Street, 26th Floor, New York, New York 10038 or by calling toll-free 888-897-6012.


'/>"/>
SOURCE Hisamitsu Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Hisamitsu Pharmaceutical Co., Inc. Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals, Inc.
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
7. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2009)..., , CHICAGO, Nov. 28 Ge...mon practice in the clinical routine when Siem...ientific Assembly and Annual Meeting of the Radiol...er 29 to December 3 at McCormick Place (Booth #825...o. With syngo. via , Siemens, new imaging ...
(Date:11/27/2009)..., , BEDFORD, Mass., Nov. 27 /PRNewswire-F...he "Company"), a supplier of precision technology ...d that an annual meeting of the Company,s sharehol.... The time and location of the meeting will be an...he Company received a requisition notice from Step...
(Date:11/27/2009)..., , SAN FRANCISCO, Nov. 27 /PRNewswire-Firs...) announced that Blair Lambert, CFO/COO, will pres... will be held at the May Fair Hotel in London, Eng.... GMT. ,, To listen to a live broadcast of The ...net, please log on to www.gymboree.com, click on "...
(Date:11/27/2009)... XenaCare Holdings has an...he Arthritis Foundation, one of the largest nonpro...and public health education. , ...- XenaCare Holdings, Inc. (OTCBB: XCHO), a company...tion of consumer healthcare products, has announce...
(Date:11/27/2009)... Voyant Health™ ann...ichigan) has licensed its TraumaCad Enterprise ort...nd workflow solution. , (...nnounced today that Spectrum Health (Grand Rapids,...rthopedic templating solution and its TraumaCad Ex...
Breaking Medicine News(10 mins):Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
... suggest some of these procedures may just be matt...ealthDay News) -- Premature births of single babie...cent years, and a new report finds that Caesarean ...," said Dr. Alan Fleischman, medical director and ...
...TER, Ill. Recent studies have linked sleep loss ...ression, obesity, diabetes, high blood pressure an...ill be presented and discussed by more than 5,000 ...ention Center from June 9 to 12. , More than 1,1...
...released today reveals a cellular mechanism involv... issue of The Journal of Neuroscience, shows that ...epilepsy, reduces alcohol intake in alcohol-depend...n involved in emotions such as stress and fear, is...
... than 40 years, Earth observing satellites have de...abled a better understanding and improved manageme...hese data are increasing daily as decision-makers ...In order to address these needs, ESA, the German S...
...d cholesterol test can help clinicians identify be...isk of heart disease, BIRMINGHAM, Ala., May 28 A...y announced it will be exhibiting its VAP,Choleste...the Moscone Convention Center in San Francisco., ...
...na, May 28 /Xinhua-PRNewswire-FirstCall/ -- China ...e Medical, or ,the Company,), a,manufacturer, mark...and,diagnostic products in China, today announced ...ver-the-Counter Bulletin,Board under the symbol ,C...
Other Medicine News:Health News:C-Sections Explain Jump in U.S. Preemie Births 2Health News:C-Sections Explain Jump in U.S. Preemie Births 3Health News:Experts to discuss sleep science and the health risks of sleep disorders in Baltimore this June 2Health News:Experts to discuss sleep science and the health risks of sleep disorders in Baltimore this June 3Health News:New study reveals brain cell mechanism of alcohol dependence 2Health News:European conference addresses increasing demand for EO data 2Health News:Atherotech to Exhibit The VAP Test at ADA 2008 Meeting in San Francisco 2Health News:China Sky One Medical, Inc. Commences Trading on the American Stock Exchange 2
(Date:11/29/2009)...WA CITY, Iowa and ST. LOUIS, Nov. 29 /PRNewswire/ ...tative imaging software for the advanced analysis ...ies, a leader in minimally invasive delivery of in...panies have signed a definitive agreement covering...chial lung navigation and biopsy system. ,, "V...
(Date:11/29/2009)...GO, Nov. 29 Researchers using func...brain activation have found that men and women res... according to a study presented today at the annua...rica (RSNA). ,, "Men may direct more attention ...o process them in terms of implications for requir...
(Date:11/27/2009)...HICAGO, Nov. 27 At the upcoming Ra...meeting starting Sunday, Royal Philips Electronics...healthcare imaging and informatics solutions desig... and care providers, by delivering meaningful imag...odular price points and easy upgradability. This ...
Breaking Medicine Technology:VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 2VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 3VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 4New Study Finds Men and Women May Respond Differently to Danger 2New Study Finds Men and Women May Respond Differently to Danger 3Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4FDA Calls for Stricter Controls on Mercury Fillings 52981 1FDA Calls for Stricter Controls on Mercury Fillings 52981 2FDA Calls for Stricter Controls on Mercury Fillings 52981 3FDA Calls for Stricter Controls on Mercury Fillings 52981 4Northwest Hospital Introduces Hyperbaric Oxygen Therapy 52978 1Northwest Hospital Introduces Hyperbaric Oxygen Therapy 52978 2Viagra Trial for Sickle Cell Lung Problems Halted 52974 1Viagra Trial for Sickle Cell Lung Problems Halted 52974 2Viagra Trial for Sickle Cell Lung Problems Halted 52974 3
...PRINCETON, N.J., June 2 Medarex, Inc.,(Nasdaq: M...oing Phase 1,study of MDX-1106 (ONO-4538: developm...human anti-PD-1 antibody. Data presented from pati... in the study included the safety,tolerability and...In,addition, preliminary evidence of anti-tumor ac...
...- Randomized Phase II data show RAD001 significant...men with newly diagnosed hormone-positive breast ... studies suggest RAD001 may help overcome a major ...stuzumab, - Novartis to further explore potentia...initiating new trial in early 2009, EAST HANOVER,...
Other Medicine Technology:Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 2Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 3Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 4Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 2Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 3Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 4Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 5Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 6Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 7Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 8Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 9
CRP Full Range (0.1-160mg/l) Calibrator Series
CRP Calibrator (Multi-point, Liquid)
Fructosamine Controls Level 3
Drug Control Level 3
Medicine Products: